Kenya HIV Therapeutics Market Analysis Report [2022-30]

Kenya HIV Therapeutics Market Analysis

$ 3999

The Kenya HIV therapeutics market is expected to reach $xx Mn by 2030, up from $xx Mn in 2022, with a CAGR of xx% from 2022 to 2030. Local Players such as Cosmos Limited, Universal Corporation, and GlaxoSmithKline Kenya dominate the HIV therapeutics market in Kenya. The government policies, funding, and initiatives by international organizations to manage HIV infections in the country propel market growth. The HIV therapeutics market in Kenya is divided into four segments: type, product, geography, end user, and distribution channel.

ID: IN10KEPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Dr. Vishwa Modhia

Buy Now

Kenya HIV Therapeutics Market Analysis Summary

The Kenya HIV therapeutics market is expected to reach $xx Mn by 2030, up from $xx Mn in 2022, with a CAGR of xx% from 2022 to 2030.

Kenya is an East African country bordered by the Indian Ocean and Lake Victoria. With 14,00,000 active HIV cases, Kenya ranks eighth among the top ten countries with the most HIV cases in 2020. Kenya ranked 13th in the world in terms of adult HIV/AIDS prevalence in 2021, with a rate of 4%. The National AIDS Control Council (NACC) held its sixth Maisha HIV/AIDS conference in Kenya in 2021, bringing together stakeholders to fight HIV/AIDS in Kenya and find effective solutions.

According to the most recent WHO data, HIV/AIDS deaths in Kenya reached 20,885 in 2020, accounting for 7.93 % of deaths. Kenya ranks 25th in the world with an age-adjusted death rate of 48.82 per 100,000 population. Kenya spent 4.3 % of its GDP on healthcare in 2021.

Market Dynamics

Market Growth Drivers

Kenya has also collaborated with international organizations such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria to expand access to HIV treatment and care. In 2019, the number of new HIV infections per year was less than a third of what it was at the peak of the country's epidemic in 1993. Kenya's Ministries, Counties, Departments, and Agencies (MDAs) use the NACC's Maisha Reporting Tool to track HIV/AIDS in the country. This enables MDAs to function as effective AIDS control units. Policymakers use the tool's localized data to inform their intervention. These factors could entice new entrants into Kenya's HIV therapeutics market.

Market Restraint

People who inject drugs share needles and syringes, which leads to an increase in HIV infections, particularly among young people. Depending on the temperature and other factors, HIV can survive in a used syringe for up to 42 days. According to data from the Ministry of Health, more than 1.1 Mn Kenyans living with HIV are on antiretroviral therapy, with 27% still unable to achieve viral suppression. These elements may deter new entrants into Kenya's HIV therapeutics market.

Competitive Landscape

Key Players

Cosmos Limited (KEN)
GlaxoSmithKline (KEN)
Universal Corporation (KEN)
ViiV Healthcare
Bristol Myers Squibb
Merck & Co.
Gilead Sciences

Healthcare Regulations and Reimbursement Policies

The Pharmacy and Poisons Board (PPB) in Kenya is the regulatory body in charge of the registration and oversight of pharmaceutical products, including HIV therapeutics. The PPB is in charge of ensuring drug safety, efficacy, and quality in Kenya. The PPB registers and approves HIV drugs, as well as monitors their market safety and quality. The PPB also establishes guidelines and standards for HIV treatment and care in Kenya. Furthermore, the Ministry of Health's National AIDS and STI Control Programme (NASCOP) is in charge of coordinating Kenya's national response to HIV/AIDS, including the regulation of HIV testing, treatment, and care services.

Through the National AIDS and STI Control Programme, the Kenyan government provides free antiretroviral therapy (ART) to all citizens and residents living with HIV (NASCOP). The National Hospital Insurance Fund, the government's public health insurance programme, covers the cost of HIV drugs and other medical services required for HIV care (NHIF). The NHIF pays for all antiretroviral drugs used to treat HIV, as well as other HIV-related medical services and supplies. Patients with HIV can seek treatment and care from either government-run or accredited private healthcare providers.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.